http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2011142254-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F15-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2011-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2013-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2011142254-A |
| titleOfInvention | MONONUCLEAR DINITROSYL IRON COMPLEXES, METHOD FOR PRODUCING MONONUCLEAR DINITROSYL IRON COMPLEXES, DONOR OF NITROGEN MONOSIDE, APPLICATION OF THE MONONUCLEAR DINITROSYL IRON COMPLEX AS A MEMBER |
| abstract | 1. A mononuclear dinitrosyl iron complex with the general formula (NH) [Fe (SR) (NO)], where R represents antimetabolites of purine DNA bases, preferably 5-nitropyridinyl, as well as 2-nitro, 3-nitro and 4- nitrophenyls and pyridinyl. 2. The method for producing mononuclear nitrosyl iron complexes according to claim 1, which consists in reducing a disulfide, preferably 5-nitropyridinyl, 2-nitro, 3-nitro and 4-nitrophenyl and pyridinyl, with hydrazine hydrate in an aqueous-alcohol solution at 18-25 ° C subsequent removal of ethanol and dissolution of the resulting product in water and reductive replacement of thiosulfate ligands in the binuclear tetranitrosyl thiosulfate sodium complex with subsequent isolation of the target product by known methods. 3. The method according to claim 2, characterized in that the process is conducted in an oxygen-free atmosphere. The method according to claim 2, characterized in that antimetabolites of purine DNA bases are used as disulfide, preferably 5-nitropyridinyl, 2-nitro, 3-nitro and 4-nitrophenyls and pyridinyl. The method according to claim 2, characterized in that hydrazine hydrate is used as a reducing agent for the disulfide. A nitrogen monoxide donor, which is a mononuclear dinitrosyl iron complex according to claim 1.7. The use of the mononuclear dinitrosyl iron complex according to claim 1 as an antitumor drug. |
| priorityDate | 2011-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 36.